Skip to main content

Cagrilintide vs FGL

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Cagrilintide

Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.

Full details →

FGL

FGL (FG Loop) is a synthetic peptide that mimics the neural cell adhesion molecule (NCAM) FG loop region. It promotes neuroplasticity and has shown cognitive-enhancing effects in research.

Full details →

Side-by-Side Comparison

AspectCagrilintideFGL
MechanismActivates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1.Binds to FGFR1 (fibroblast growth factor receptor 1) to activate downstream signaling cascades that promote neurite outgrowth, synaptic plasticity, and neuronal survival.
Typical DosageClinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined.Research protocols have used subcutaneous doses ranging from 1-10mg. Intranasal administration also studied. Optimal dosing not established.
AdministrationSubcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved.Subcutaneous injection or intranasal administration. Research compound with limited human dosing data.
Side EffectsNausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially.Limited human data available. Animal studies show good tolerability.
Best For

Key Differences

Unique to Cagrilintide:

Unique to FGL:

Detailed Analysis

Cagrilintide and FGL are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose Cagrilintide for Fat Loss. Choose FGL for Cognitive Performance.

Ready to Learn More?